Financial Health Assessment: Ampere Analysis Limited

1. Financial Health Score: B+

Explanation: Ampere Analysis Limited presents the vital signs of a vigorously growing business with a highly resilient revenue model, but it is currently experiencing "growing pains" that are compressing its profitability margins. The company's top-line revenue is expanding rapidly, and its cash reserves remain robust. However, heavy reinvestment in staff and technology, combined with significant dividend payouts, has led to a noticeable contraction in operating margins and a reduction in overall net assets. Like an athlete training at high altitude, the company is building endurance for the future, but the immediate vital signs show some financial shortness of breath.

2. Key Vital Signs

• Revenue Pulse (Turnover): £11.87 million — The patient's pulse is strong and accelerating. Revenue has grown by a healthy 17% year-on-year (up from £10.18 million in 2024). This indicates robust market demand and successful client acquisition.
• Profitability Blood Pressure (Operating Profit Margin): 1.49% — This is a symptom of mild hypertension. While the company is profitable, the margin has narrowed from 1.94% the previous year. On £11.87 million of revenue, the operating profit is roughly £177k, meaning the business is converting less than 2 pence of every pound earned into operating profit.
• Cash Hydration (Cash at Bank): £3.78 million — The company is well-hydrated. Though down from £4.58 million in 2024, a cash reserve of £3.78 million against £2.50 million in debtors provides excellent liquidity and a strong buffer against unforeseen shocks.
• Net Asset Body Mass (Shareholders' Funds): £846,765 — The patient has lost some weight here. Shareholders' funds have dropped from £1.46 million to £846k. This is primarily a symptom of the £600,004 dividend payout, which effectively transferred a large portion of the company's equity health directly to the shareholders.
• Revenue Immunity (Subscription Model): 95% — An exceptional vital sign. With 95% of revenues coming from subscriptions (typically 1-3 year contracts), the company has a highly predictable and recurring revenue stream, making it highly immune to sudden market sickness.

3. Diagnosis

Diagnosis: Acute Growth Pains with Strategic Dividend Extraction

The financial data reveals a business that is fundamentally healthy at its core but is experiencing significant strain from its current growth phase.

The primary symptom is margin compression. Administrative expenses surged by roughly £1.7 million year-on-year, entirely absorbing the £1.7 million in additional revenue generated. The strategic report clearly identifies the cause: significant investments in staff and technology to support new product roll-outs. In medical terms, the company is consuming vast amounts of energy (capital) to build new muscle (products and market share), leaving little surplus fuel (profit) in the system.

Furthermore, the drop in net assets is not a symptom of operational failure, but rather a result of aggressive dividend extraction. The company paid out £600,004 in dividends—more than three times its operating profit. This was sustained by the company's robust cash flow and strong balance sheet from prior years, but it is not a sustainable practice indefinitely unless profitability scales rapidly.

Finally, there is a mild foreign exchange allergy. The increasing proportion of US revenue creates FX exposure, though management is treating this with hedging facilities.

4. Recommendations

1. Monitor the Margin Diet: While reinvesting for growth is a sound strategy, management must set timelines for when the new investments (staff, technology, advertising product) should start yielding improved operating margins. A 1.49% margin leaves very little room for error; if revenue stumbles, the company could quickly post a loss.
2. Moderate Dividend Prescriptions: The £600k dividend was supportable given the prior year's cash position, but paying dividends that exceed operating profit depletes the company's equity base. Future dividends should be tied more closely to actual operating profit until margins improve.
3. Continue FX Hedging Therapy: As US revenues grow, currency fluctuations will increasingly distort the true underlying performance of the business. Maintaining strict hedging protocols is essential to prevent FX volatility from infecting the P&L.
4. Capitalize on Market Momentum: The outlook is very positive with key clients renewing and strong growth in video games and sports. The company should leverage its newly developed advertising product to increase top-line revenue without proportionately increasing fixed costs, which will naturally heal the margin compression.